key: cord-0721966-2vfh1bhg
authors: Lim, P. N.; Wylie, G.
title: Symmetrical drug‐related intertriginous and flexural exanthema like eruption associated with COVID‐19 vaccination
date: 2021-08-31
journal: Clin Exp Dermatol
DOI: 10.1111/ced.14898
sha: c17c40f42e87aeae9ce90f576e3b25bef65edf73
doc_id: 721966
cord_uid: 2vfh1bhg

This is a case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption following ChAdOx1 nCoV‐19 (AstraZeneca‐Oxford) vaccination. Investigations, including repeated skin swabs, ruled out an infectious cause. He was subsequently treated with oral prednisolone, which led to a resolution of his symptoms.[Image: see text]

Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination doi: 10.1111/ced.14898

Dear Editor, A 61-year-old patient presented with a 4-week history of tender rash on the bilateral groins, with no associated rash elsewhere. The rash had appeared 1 day after he had received the second ChAdOx1 nCoV-19 (AstraZeneca-Oxford) vaccine. His medical history included type 2 diabetes, which had been well-controlled with oral antidiabetic medications.

Physical examination revealed a florid, symmetrical rash with a well-demarcated inflammatory border on both groins (Fig. 1a) and well-defined patches of erythema involving the gluteal area (Fig. 1b) . This was associated with superficial erosions, skin desquamation and crusting on the scrotal skin. There was no mucosal involvement. Skin swabs and scrapings were negative for bacterial and fungal growth, respectively, and viral PCR for herpes and varicella zoster viruses was also negative. Blood tests showed normal levels of inflammatory markers but slightly raised white cell and neutrophil counts. Zinc level was normal. The patient declined a diagnostic skin biopsy.

In view of the clinical history and examination finding, a diagnosis of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)-like eruption was considered. The patient was subsequently treated with oral prednisolone 30 mg for 2 weeks, then 20 mg for 2 weeks, followed by a taper of 5 mg/week. He was also prescribed betamethasone/clotrimazole cream (Lotriderm; Organon Pharma, Hoddesdon, Hertfordshire, UK) and potassium permanganate soaks to weeping areas. This led to a significant improvement after 1 month of treatment.

The AstraZeneca-Oxford vaccine is a recombinant, replication-deficient chimpanzee adenoviral vector vaccine that contains the genetic material to encode the S glycoprotein of SARS-CoV-2. The vaccine was approved in late December 2020 by the Medicines and Healthcare products Regulatory Agency after being shown to be safe and effective following an interim analysis of phase III trials. 1 Cutaneous reactions are less commonly reported with adenoviral vaccines such as AstraZeneca-Oxford compared with messenger RNA (mRNA) vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moder-naTX). Vaccine-associated cutaneous reactions commonly include delayed large local reactions, local injection-site reactions, urticaria and maculopapular reactions. 2 AstraZeneca-Oxford has been associated with a rare risk of thromboembolism and vaccine-induced prothrombotic immune thrombocytopenia, which may appear as purpura, erythema and oedema of the extremity. 3 Other cutaneous reactions include injection-site reactions and delayed local reactions. 3, 4 AstraZeneca-Oxford contains the excipient polysorbate 80 (E433), which is thought to induce hypersensitivity reactions such as dermatitis, urticaria and anaphylactoid eruptions. 3 This is different from mRNA vaccines in which the excipient polyethylene glycol is thought to be the cause. 2 SDRIFE is a type IV delayed hypersensitivity drug reaction characterized by a symmetrical eruption affecting the inguinal/genital, gluteal/perianal areas and other intertriginous areas such as the axillae, elbows and knees, and typically occurs hours to days following exposure to a systemic agent without systemic involvement. Common drug causes are b-lactam antibiotics, terbinafine, iodine radio-contrast media and monoclonal antibodies such as infliximab. 5 To our knowledge, this is only the second case of SDRIFE-like eruption secondary to COVID-19 vaccines. The first case was reported following administration of CoronoVac vaccine, which contains an inactivated form of the COVID-19 virus. This case report adds to the collection of cutaneous reactions assocated with AstraZeneca-Oxford. P. N. Lim 1 and G. Wylie 1

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases

Cutaneous adverse effects of the available COVID-19 vaccines

Delayed cutaneous reaction to ChAdOx1 nCoV-19 vaccine: is it an 'AstraZeneca arm'?

A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE)